STOCK TITAN
  1. Home
  2. News
  3. BLRX

BioLineRX Ltd - BLRX STOCK NEWS

Welcome to our dedicated page for BioLineRX news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on BioLineRX stock.

BioLineRx Ltd. (NASDAQ: BLRX) is a commercial-stage biopharmaceutical company based in Modi'in, Israel, with operations extending to the United States. The company specializes in developing life-changing therapies for oncology and rare diseases. BioLineRx's flagship product, APHEXDA® (motixafortide), has gained approval in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma patients.

Currently, the company is advancing a robust pipeline of investigational medicines targeting sickle cell disease, pancreatic cancer, and other solid tumors. One of their notable clinical-stage therapeutic candidates is motixafortide (BL-8040), a novel peptide showing promise in stem-cell mobilization and solid tumors. Another key candidate is AGI-134, an immuno-oncology agent dedicated to treating solid tumors.

BioLineRx recently announced definitive agreements with institutional investors for the issuance and sale of its American Depositary Shares (ADSs) and warrants. This equity transaction, combined with financial resources from an existing debt facility, positions the company well for the commercialization of APHEXDA and the advancement of its other pipeline programs. Additionally, the company is exploring motixafortide's potential in supporting gene therapy for sickle cell disease, collaborating with leaders in the gene therapy field such as St. Jude Children's Research Hospital and Washington University School of Medicine.

BioLineRx has also received recent notifications and presented new data at various esteemed conferences such as the American Society of Clinical Oncology (ASCO) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). These efforts underscore the company's commitment to bringing innovative therapies from the bench to the bedside.

To access more information about BioLineRx, visit their official website or follow them on Twitter and LinkedIn.

News

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Rhea-AI Summary
BioLineRx (BLRX) reported significant commercial progress for APHEXDA®, securing payer coverage for ~95% of covered lives in the U.S. They announced the first patient dosed in a Phase 2b clinical trial for motixafortide in pancreatic cancer, along with continued support for partner Gloria Biosciences in China. Financially, the company had total revenues of $4.8 million in 2023, with a net loss of $60.6 million. The company's vision of bringing innovative therapies to market and their progress in various clinical programs demonstrate a promising future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.77%
Tags
earnings
-
News

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Rhea-AI Summary
BioLineRx to Release Audited Financial Results for 2023 on March 26, 2024, Hosting Conference Call with CEO Philip Serlin at 08:30 a.m. EDT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences earnings
-
News

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Rhea-AI Summary
BioLineRx receives a Notice of Allowance from the USPTO for a patent covering the manufacturing process of motixafortide, extending its IP portfolio until December 2041. The company has secured Orphan Drug and New Chemical Entity market exclusivity for motixafortide, enhancing its commercial potential in oncology and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
News

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Rhea-AI Summary
BioLineRx Ltd. announced the initiation of the CheMo4METPANC Phase 2 trial in collaboration with Columbia University, evaluating motixafortide with a PD-1 inhibitor and standard chemotherapies for pancreatic cancer. Positive pilot phase data showed a 91% disease control rate, with 64% experiencing partial responses. Motixafortide, the company's lead candidate, was FDA-approved for stem cell mobilization in multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
clinical trial
-
News

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Rhea-AI Summary
BioLineRx Ltd. announces presentation of new post-hoc subgroup analyses and pharmacodynamic data on APHEXDA for CD34+ hematopoietic stem cell mobilization in multiple myeloma patients at the 2024 Tandem Meetings. The Phase 3 GENESIS trial results show positive pharmacokinetic and pharmacodynamic data, highlighting the efficacy of motixafortide + G-CSF over placebo + G-CSF mobilization for all patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.61%
Tags
none
-
News

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Rhea-AI Summary
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) announced the dosing of the first patient in a Phase 1 clinical trial evaluating motixafortide for CD34+ hematopoietic stem cell mobilization for gene therapies in sickle cell disease. The trial aims to identify more efficient mobilization regimens for patients with sickle cell disease choosing gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
clinical trial
News

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Rhea-AI Summary
BioLineRx Ltd. (NASDAQ: BLRX) received FDA approval for APHEXDA® in combination with Filgrastim for stem cell mobilization in multiple myeloma patients. They also closed an exclusive license agreement for motixafortide in the Asia region, alongside strategic equity investment. They presented encouraging data at AACR from a pilot phase of a randomized phase 2 combination trial with motixafortide in first-line PDAC. Additionally, they began enrollment for a phase 1 trial evaluating motixafortide for stem cell mobilization in sickle cell disease patients seeking gene therapy. The company will host a conference call today, November 20, at 10:00 a.m. EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
earnings
-
News

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Rhea-AI Summary
BioLineRx Ltd. (NASDAQ: BLRX) to Release Q3 2023 Financial Results on Nov 20, 2023; CEO to Host Conference Call at 10:00 a.m. EST
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences earnings
-
News

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Rhea-AI Summary
BioLineRx Ltd. has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. for the development of motixafortide in Asia. The agreement includes a $15 million upfront payment, an equity investment of $14.6 million, and potential milestones and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.78%
Tags
none
News

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

Rhea-AI Summary
BioLineRx closes exclusive license agreement with Gloria Biosciences for development of motixafortide in Asia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
none

FAQ

What is the current stock price of BioLineRX (BLRX)?

The current stock price of BioLineRX (BLRX) is $0.1054 as of January 29, 2025.

What is the market cap of BioLineRX (BLRX)?

The market cap of BioLineRX (BLRX) is approximately 16.3M.

What does BioLineRx Ltd. specialize in?

BioLineRx Ltd. specializes in developing therapies for oncology and rare diseases.

What is APHEXDA®?

APHEXDA® (motixafortide) is a stem cell mobilization agent for autologous transplantation in multiple myeloma patients.

What are some of BioLineRx's key therapeutic candidates?

Key therapeutic candidates include motixafortide (BL-8040) and AGI-134, aimed at treating solid tumors and supporting stem cell mobilization.

Where is BioLineRx Ltd. headquartered?

BioLineRx Ltd. is headquartered in Modi'in, Israel.

Who are BioLineRx's collaboration partners for gene therapy?

BioLineRx collaborates with St. Jude Children's Research Hospital and Washington University School of Medicine for gene therapy.

What recent financial actions has BioLineRx taken?

BioLineRx announced the issuance and sale of ADSs and warrants, along with utilizing an existing debt facility for financial resources.

What was discussed at the recent conferences BioLineRx attended?

BioLineRx presented new data on motixafortide and its applications in oncology at the ASCO and ISPOR conferences.

What is AGI-134?

AGI-134 is an immuno-oncology agent in development for treating solid tumors.

Can I invest in BioLineRx Ltd.?

Yes, BioLineRx Ltd. is publicly traded on NASDAQ under the symbol BLRX.

Where can I find more information about BioLineRx?

To learn more about BioLineRx, visit their official website at www.biolinerx.com and follow them on Twitter and LinkedIn.
Stock BLRX logo
BioLineRX Ltd

Nasdaq:BLRX

BLRX Rankings

#5450 Ranked by Market Cap
N/A Ranked by Dividends

BLRX Stock Data

16.26M
135.51M
8.54%
3.09%
1.33%
Biotechnology
Healthcare
Link
United States of America
Hevel Modi'in